Astellas' Xospata fails to extend survival in leukemia study
- Astellas' (OTCPK:ALPMF) Xospata (gilteritinib) in combination with azacitidine did not meet the primary endpoint of overall survival at an interim analysis of Phase 3 trial, LACEWING in acute myeloid leukemia (AML) patients.
- Independent data monitoring committee recommended terminating the study for futility; Astellas has stopped enrollment.
- Trial involved 250 newly diagnosed FLT3 mutation-positive AML patients who were ineligible for intensive induction chemotherapy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.